Pediatrics


Showing 511-520 of 844 Results

  • Sean McGhee

    Sean McGhee

    Clinical Professor, Pediatrics - Immunology

    Current Research and Scholarly InterestsBioinformatics

  • Mark McGovern

    Mark McGovern

    Professor of Psychiatry and Behavioral Sciences (Public Mental Health and Population Sciences) and, by courtesy, of Pediatrics

    BioDr. Mark McGovern is a Professor and the Associate Chair of Translation and Implementation Research in the Department of Psychiatry & Behavioral Sciences and, by courtesy, the Department of Medicine at Stanford University School of Medicine.

    Most people who need health care do not receive it. And of those who do, wide variation exists in access to care and the quality of the care they receive in health care systems, both private and public. Dr. McGovern is a leader in using rigorous methods of implementation science to close these gaps in health care delivery.

    His mission is to get the best health care possible to the people who need it the most.

    Dr. McGovern's primary focus is the implementation and sustainment of evidence-based interventions and guideline adherent care in public and private health care systems and organizations. Within the hub of the Stanford Center for Dissemination and Implementation (CDI) which he directs, Dr. McGovern is the Principal Investigator (PI) and leads three national implementation research and practice centers: The Center for Dissemination and Implementation At Stanford (C-DIAS); The Research Adoption Support Center (RASC); and, the Mental Health Technology Transfer Center Network Coordinating Center (MHTTC). The 3 centers are federally-funded, respectively by the National Institute on Drug Abuse (P50DA05402), the National Institutes of Health Healing Addiction Long Term (HEAL) initiative (U2CDA057717), and the US Department of Health and Human Services Substance Use and Mental Health Services Administration (H79SM081726). Dr. McGovern is also the PI on a multi-site adaptive implementation trial across a state system of care, which aims to integrate addiction medications for persons with opioid use disorder who are receiving services in specialty or primary care organizations (R01DA052975). In addition, he addresses implementation challenges in federally-qualified health centers (FQHCs) across the State of California, in the Stanford Division of Primary Care and Population Health, and in specialty addiction and mental health treatment organizations nationwide. He leads, facilitates and/or actively engages networks advancing implementation science in health, including the NIDA Clinical Trials Network Translation & Implementation Special Interest Group, the NIDA Clinical Trials Western States Node Translation & Implementation Workgroup, the Stanford University Network for Dissemination & Implementation Research (SUNDIR), the VA Palo Alto HSR&D Center for Innovation to Implementation, and the Stanford Medicine Center for Improvement. He is on the Core Faculty of the National Institute of Mental Health Implementation Research Institute at the Washington University in St. Louis. Dr. McGovern is a collaborator on multiple projects as a co-investigator, consultant, or advisory board member. He is a mentor to numerous individuals across the country and at Stanford, from university undergraduates to mid-career faculty and clinical administrators at academic institutions and health care systems nationwide.

  • Rebecca Mckenzie

    Rebecca Mckenzie

    Clinical Assistant Professor, Pediatrics - General Pediatrics

    Current Research and Scholarly InterestsPediatric liver transplant, outcomes, adherence, transition, liver failure

  • Peter Meaney

    Peter Meaney

    Clinical Professor, Pediatrics - Critical Care

    Current Research and Scholarly InterestsDr. Meaney is a nationally and internationally recognized pediatric resuscitation scientist, and his current focus is on improving care for seriously ill children at the community clinic and district hospital level in low and middle income countries. Dr Meaney seeks to conduct the necessary research to pioneer, implement and evaluate innovative yet relevant and practical solutions to improve the quality of care for seriously ill or injured children worldwide.

  • Rishi Mediratta

    Rishi Mediratta

    Clinical Associate Professor, Pediatrics

    Current Research and Scholarly InterestsI have developed a new promising neonatal mortality prediction score at the University of Gondar Neonatal Intensive Care Unit (NICU) in Gondar, Ethiopia. The score predicts approximately 84% of neonatal deaths in the NICU using clinical variables. I have a dataset over 800 NICU admissions in Gondar. I am recruiting scholars who are interested in conducting clinical and epidemiological research to validate, refine, and implement the mortality score to reduce neonatal mortality in Ethiopia.

  • Eric Meffre

    Eric Meffre

    Professor of Medicine (Immunology and Rheumatology)

    BioDr. Meffre obtained his PhD in Immunology from the Université d’Aix-Marseille in France before he moved to the USA as a postdoc fellow in the laboratory of Dr. Michel Nussenzweig at The Rockefeller University in New York City. He became an assistant professor at Cornell University in 2003 before being recruited at Yale University as associate professor in 2009. He was tenured at Yale in 2014 before he joined the Department of Medicine/Division of Immunology and Rheumatology at Stanford University as a tenured full professor in 2022.

    Dr. Meffre’s work focuses on the etiology of autoimmune syndromes and the roles played by B cells in these diseases. His group characterized the abnormal selection of developing autoreactive B cells in patients with rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), type 1 diabetes (T1D), multiple sclerosis (MS) and Sjögren’s syndrome, resulting in large numbers of autoreactive naïve B cells accumulating in the patient’s blood. Hence, these autoreactive B cells may present self-antigens to T cells and initiate autoimmune diseases. These early B cell tolerance defects are likely primary to these autoimmune diseases and may result from genetic factors such as the 1858T PTPN22 allele that segregates with RA, SLE and T1D and correlate with an impaired removal of developing autoreactive B cells.
    His research goals also consist in characterizing the molecules and pathways involved in the establishment of B cell tolerance and the removal of developing autoreactive B cells generated by random V(D)J recombination through the investigation of rare patients with primary immunodeficiency (PID) enrolled through an international network. Alteration of B cell receptor (BCR) or Toll-like receptor (TLR) signaling in PID patients results in a defective central B cell tolerance and a failure to counterselect developing autoreactive B cells in the bone marrow. In contrast, functional and suppressive regulatory T cells play a key role in preventing the accumulation of autoreactive clones in the mature naïve B cell compartment. The recent development of humanized mouse models recapitulating early B cell tolerance checkpoints and their defects in autoimmune settings allow further in-depth investigation of tolerance mechanisms and the development of novel approaches to restore defective central and peripheral B cell tolerance checkpoints and thwart autoimmunity.

  • Kara Meister, MD, FAAP, FACS

    Kara Meister, MD, FAAP, FACS

    Assistant Professor of Otolaryngology - Head & Neck Surgery (OHNS) and, by courtesy, of Pediatrics

    BioKara D. Meister, MD, FAAP, FACS is a pediatric otolaryngologist and head & neck surgeon. She received her medical degree from Medical University of South Carolina and completed her otolaryngology residency at University of Pittsburgh. She completed a NIH-funded fellowship in head and neck research at the University of Pittsburgh. Dr. Meister then went on to complete a pediatric otolaryngology fellowship at Lucile Packard Children’s Hospital Stanford.

    She is currently an Assistant Professor in the Department Otolaryngology, Division of Pediatric Otolaryngology, at Stanford University. Dr. Meister’s research interests include thyroid cancer, head & neck masses, Graves' disease. She has a special interest in the influence of the environment and pollutants (such as microplastics) on health. She currently serves as the Co-Clinical Chief of Pediatric Otolaryngology. Dr. Meister completed additional training in innovation through the Stanford Biodesign Faculty Fellowship.

    Her clinical interests include the treatment of patients with head and neck masses including thyroid nodules and cancer. She is Co-Director, Surgical, of the Children's Thyroid Center at Lucile Packard Children’s Hospital Stanford and is a participating surgeon in the Aerodigestive and Airway Reconstruction Center at Stanford Children’s Health. She is co-editor of the textbook "Pediatric Bronchoscopy for Clinicians" and enjoys advocacy work with the American Academy of Pediatrics Button Battery Taskforce.

    Dr. Meister is a member of the American Thyroid Association (ATA) where she serves on the Diversity, Equity, and Inclusion committee and is a member of the ATA Guidelines Writing Group for Thyroid Disease & Pregnancy. She is a member of the pediatric committee of the American Head and Neck Society. She is an author and speaker on masses and tumors of the head and neck, thyroid disease, and thyroid cancer in children and adolescents. In collaboration with SHC, she offers novel treatment for thyroid problems in children and adolescents including radiofrequency ablation of thyroid nodules.

    Dr. Meister lives in Woodside with her husband, 3 children, and Rooney the dog.

    Clinical Expertise:
    Children's Thyroid Center, Co-Director, Surgical
    Thyroid nodules
    Thyroid cancer - papillary, follicular, and medullary
    Surgical management of hyperthyroidism and Grave's disease
    MEN syndrome
    Head and Neck masses
    Congenital neck masses such as branchial cleft cyst, thyroglossal duct cyst
    Pediatric Head and Neck cancer
    Airway evaluation and reconstruction, voice and swallowing problems, and Aerodigestive
    Fetal Airway and Exit Team

  • Mads Melbye

    Mads Melbye

    Visiting Professor, Pediatrics - Neonatology

    BioMads Melbye, MD, DMSc, is visiting Professor in the Department of Pediatrics at Stanford University School of Medicine. He is also Director of the Danish Cancer Institute (DCI), Research Director at the Danish Cancer Society in Denmark, and Professor in Medical Epidemiology at the Norwegian University of Science and Technology. From 2016-2020 he was President and CEO at Statens Serum Institut, Copenhagen, Denmark. Previous positions at e.g. the National Cancer Institute, NIH, USA, before he became State Epidemiologist in Denmark, and later Head of Department of Epidemiology Research, and Division Director of Epidemiology and Disease Surveillance, Statens Serum Institut. Previous academic positions as Danish Research Council Professor, NORFA professor, and Foreign Adjunct Professor at Karolinska Institute in Sweden. He has written more than 700 publications (H-index: 115/141 (Web of Science/Google scholar) and is the Dane with most papers in high impact journals in general medicine (NEJM, Lancet, JAMA). He is among the worlds top 2% of scientists as listed in the AD Scientific Index 2023. He is knighted by Her Majesty Queen Margrethe II of Denmark, and has received e.g. the Novo Nordisk Prize, the large Erhoff Prize, and the Anders Jahre Prize (young researchers). He is e.g. chairman of the scientific committee at the Danish Health Insurance Fund, member of the scientific advisory board for Oslo University Hospital, member of the A.P. Møller and Chastine Mc-Kinney Møller Foundation (medicine), and board member of the Norwegian Cancer Registry. Has previously served as e.g. chairman of the Governing Council, WHO's International Agency for Research on Cancer in Lyon, France, chairman of the Nordic Medical Research Council’s coordinating body (NOS-M), vice-chairman of the Danish Medical Research Council, chairman of the Ministry of Science, Technology and Innovation's committee on Registry Research (KOR), chairman of the Scientific Council, IARC, Lyon, France, and member of the Novo Nordisk Prize Committee. Together with Professor Stephen Quake he founded Mirvie Inc. in 2018, a biotech company that creates precise, actionable, and non-invasive tests for maternal-fetal health.

  • Elizabeth Mellins

    Elizabeth Mellins

    Member, Bio-X

    Current Research and Scholarly InterestsMolecular mechanisms and intracellular pathways of MHC class II antigen processing and presentation, with a focus on B cells; mechanisms underlying HLA allele association with disease; disease mechanisms in systemic juvenile idiopathic arthritis, including an HLA-linked complication; monocytes as drivers or suppressors of auto-inflammation in systemic juvenile idiopathic arthritis and pediatric acute neuropsychiatric syndrome.